Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Pfzer’s CEO sold 60% of his share after yesterday’s news. Hahah sounds like he know their drug sucks
Webinar on Oregon measure 109
Nice! Able to scoop up at .80 perfect timing my funds became available
Just a reminder: Thanks to the Shroom Boom, This Small Stock Could Soar
https://www.nasdaq.com/articles/thanks-to-the-shroom-boom-this-small-stock-could-soar-2020-10-13
Already 15k volume pre market
Already $1.02 showing on my TD ameritrade
Just wondering how is this going to nasdaq?
Psyched: Oregon Legalizes Psilocybin, Washington DC Decriminalizes Psychedelics, Cybin And Entheon To Go Public
5:47 pm ET November 7, 2020 (Benzinga)
Oregon has become the first state in US history to set up a program that regulates psilocybin, the active psychedelic ingredient in “magic mushrooms.”
Measure 109 was approved by 55.8% of voters in a ballot vote on Election Day.
The measure creates a state-licensed psilocybin-assisted therapy system. Patients over the age of 21 will be allowed to buy, possess and use psilocybin under the supervision of trained facilitators, while manufacture, delivery and administration of the drug will be allowed at supervised, licensed facilities.
“Now there is a new form of hope for all Oregonians and those willing to travel to Oregon rather than places like Jamaica where psychedelic retreats are already legal,” said Mike Arnold, Founder and President of Silo Wellness, an Oregon-based company with retreat operations in Jamaica.
Field Trip Health (CSE: FTRP) (OTC: FTRPF) also announced intentions to establish therapy clinics in the Beaver State, stating that it is “in advanced stages of identifying potential sites for Field Trip Health centers to treat people in Oregon with psilocybin therapies.”
The approved legislation sets up a two-year period to develop the program and put it into action.
Oregonians also approved separate legislation, called Measure 110, which decriminalizes possession and use of all scheduled drugs including heroin, cocaine and methamphetamine.
Washington DC Decriminalizes Psychedelic Plants And Fungi
Voters in the District of Columbia have approved an initiative that aims to effectively decriminalize the use of several psychedelic substances.
Initiative 81 makes non-commercial possession, distribution, purchase and cultivation of psychedelic and hallucinogenic plants and fungi a lowest law enforcement priority for the Metropolitan Police Department.
The measure includes a non-binding call for the D.C. attorney general and U.S. attorney for DC to "cease prosecution of criminal charges involving these substances,” which are also referred to as “entheogens.”
The ballot initiative was approved by 76% of voters.
Initiative 81 does not change penalties regarding these plants, nor does it allow commercial sales.
The measure is similar to those taken by other jurisdictions like Denver; Oakland and Santa Cruz in California, and Ann Arbor, MIch., in recent years.
Cybin And Entheon Biomedical To Go Public Next Week
Two psychedelics companies announced plans to begin public listings of their stock, starting next week.
Cybin, a Toronto-based psychedelics research company, announced on Thursday it has completed a reverse take-over with Clarmin Explorations Inc.
The company’s stock will be available on the NEO exchange on November 10 under the symbol CYBN.
Last week, the company announced the closing of a private offering for CA$45 million ($34.2 million).
Cybin is currently working towards a Phase 2 clinical trial to study psilocybin use for major depressive disorder. The trial will include 120 patients taking four doses of a sublingual film containing psilocybin over a four-month period.
Entheon Biomedical also announced a go-public date on Thursday.
The company closed its reverse acquisition with MPV Exploration Inc. and announced that its stock will be available on the Canadian Securities Exchange on November 12 under the symbol ENBI.
Entheon is a psychedelic-drug development company focused on developing DMT-based medicines for substance abuse disorder. DMT, or N,N-Dimethyltryptamine, is a short-acting psychedelic molecule present in ayahuasca, an hallucinogenic beverage traditionally used by indigenous people of the Amazon basin.
MindMed Completes LSD Study
MindMed (NEO: MMED) (OTCQB: MMEDF) completed a phase 1 study on LSD. The study examined different doses of the drug in healthy individuals to understand how its effect varies between doses.
“Maximal good drug effects were reached at a 100ug dose. However, an experiential dose of 200ug LSD was shown to induce greater ego dissolution than a lesser 100ug dose,” said a press release.
Ego dissolution is believed to be one of the key elements behind the therapeutic potential of psychedelic-assisted therapy.
The company now expects to move to a Phase 2b clinical trial to assess the efficacy of LSD-assisted therapy for anxiety disorders.
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Joe Rogan tweeted about Psychedelics. Hopefully we can get MMED on his show.
Wow another premarket buy now price is .99
Already 0.99 on TD
Premarket buy showing .8850
Why is Mindmed already have volume like its Compass
Passed!!!!
Looks like a good time for psychedelics!
https://twitter.com/jfberke/status/1323818979102740480?s=21
With our sights set on a NASDAQ up-listing, our newly announced funding will bolster the @MindMedCo team in our mission to Discover, Develop, and Deploy psychedelic inspired medicines to alleviate suffering and improve health.
https://twitter.com/mindmedco/status/1323391938800742401?s=21
Look Revive and J&J mentioned in a news together...
Psychedelic Therapies Become New Biotech Hotspot Amid New Legitimacy
https://www.prnewswire.com/news-releases/psychedelic-therapies-become-new-biotech-hotspot-amid-new-legitimacy-301164588.html
Psychedelic Therapies Become New Biotech Hotspot Amid New Legitimacy
https://www.prnewswire.com/news-releases/psychedelic-therapies-become-new-biotech-hotspot-amid-new-legitimacy-301164588.html
Canaccord PT $1.75 => $2 on account of upsized raise
https://twitter.com/juliaskripkaser/status/1323281607235612672?s=21
Nice! Then also Friday they got that other funding too for more studies!
Next weeks is 8 weeks of Nasdaq application. They already released news today of having 50m cash...
Sounds like we rocketing!
$50M in cash before uplist. Nice!
News: MindMed | $MMED $MMEDF
— Psychedelic Finance (@Psych_Fin) October 30, 2020
Closing on $28.75M CAD in new capital.
This gives them $50.1M CAD in total capital to fund their multiple clinical trials around psychedelic derived medicines.https://t.co/aWlMNfiNyW
I meant to place this on MMEDF my bad.
MindMed Closes Upsized Financing of CAD $28.75m With Strong Institutional Demand for Psychedelic Medicines https://finance.yahoo.com/news/cu-inc-announces-debenture-issue-002600028.html
MindMed Closes Upsized Financing of CAD $28.75m With Strong Institutional Demand for Psychedelic Medicines
https://finance.yahoo.com/news/cu-inc-announces-debenture-issue-002600028.html
Were getting pre market buys?
Good or bad? Isn’t that one of the uplist requirements?
Revive Tweeted this article this morning. Am I reading it right? It does say 200 pts...
https://www.biospace.com/article/biopharma-update-on-the-novel-coronavirus-october-27/?fbclid=IwAR0ma5wa8LkO0bZDYsxMOp0TWl6kHqX-mVvjTGRsWBW7Kpc3-3NH2mXGP_E
Added 420 because i need this to get higher :)
Dr Yo Responded and this is perfect because he is doing a Covid 19 long haulers project and he is very aware of mental illnesses on the rise! $MMED $MMEDF
Dr Yo of DrYoShow opened his DMs so I took a chance and promoted Mindmed. Gave twitter handle and JR Rhan’s. Hopefully they’ll be on his show soon.
https://twitter.com/yodoctoryo/status/1321252165017546752?s=21
MindMed Files Final Prospectus In Connection With Bought Deal Equity Financing
FINANCING TO SUPPORT THE DEVELOPMENT OF MINDMED'S GROWING PIPELINE OF PSYCHEDELIC INSPIRED MEDICINES AND EXPERIENTIAL THERAPIES
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
http://tools.prnewswire.com/en/live/21240/release/20201027C7250
Idk but this week seems like a good time to drop some news.. big news!
Join me live on Thursday, Oct. 29 at 11AM ET on OGIG and JETS – Internet and E-commerce and Airline Industry with Frank Holmes CEO and CIO, U.S. Global Investors. Register here https://t.co/6OxNk2PjxI. Follow @O_Shares for more.
— Kevin O'Leary aka Mr. Wonderful (@kevinolearytv) October 27, 2020
Vic Neufeld is back—this time hoping to replicate the success he brought to $APHA in its early years to $HAVN Life Sciences. So far, so good: the stock closed at new high yesterday @$1.00/sh and has already made partnerships with psilocybin leaders such as $RVV $RVVTF. We're 👀 pic.twitter.com/Wv1mia443L
— The Dales Report (@TheDalesReport) October 27, 2020